Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Haemophilus influenzae type b vaccine · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | ACTIVE_COMPARATOR | - |
| Arm 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Haemophilus influenzae type b (Hib) vaccine | BIOLOGICAL | Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines |
Inclusion Criteria: * Infants 365-569 days of age. Exclusion Criteria: * Subjects who already received a booster dose of Hib vaccine. * History of serious reaction(s) following vaccination. * Any vaccination within 7 days of study vaccination. * Known or suspected immune impairment.
Haemophilus influenzae type b (Hib) is a vaccine developed by Novartis AG for the prevention of Haemophilus influenzae type b infections, including invasive Hib disease. It is indicated for use in infants and children to protect against infections caused by the Hib bacterium, such as meningitis and pneumonia.
Haemophilus influenzae type b is developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The vaccine is being investigated for the prevention of Haemophilus influenzae type b infections in pediatric populations.
Haemophilus influenzae type b is in Phase 3 clinical development. It has completed two Phase 3 trials and one Phase 1 trial, with no active trials currently ongoing. The vaccine is investigational and has not been approved for use in any market.
Haemophilus influenzae type b has completed three clinical trials: NCT00734565 (Phase 1, safety and reactogenicity), NCT00808392 (Phase 3, safety and immunogenicity), and NCT01044316 (Phase 3, comparing two doses of the vaccine). A fourth trial, NCT01226953, evaluated a booster dose in infants. All trials were conducted in China.
Haemophilus influenzae type b is a monovalent conjugated vaccine that works by stimulating the immune system to produce antibodies against the Haemophilus influenzae type b bacterium. The vaccine is conjugated to a carrier protein, either diphtheria toxin CRM197 or tetanus toxoid, to enhance the immune response in infants.
Yes, Haemophilus influenzae type b is commonly referred to as a Hib vaccine. It is designed to prevent infections caused by the Haemophilus influenzae type b bacterium, including invasive diseases such as meningitis and epiglottitis. The vaccine is being studied in pediatric populations in China.